Literature DB >> 9101497

Risk factors for osteonecrosis in systemic lupus erythematosus.

M A Mont1, C J Glueck, I H Pacheco, P Wang, D S Hungerford, M Petri.   

Abstract

OBJECTIVE: To study clinical and laboratory factors in patients with systemic lupus erythematosus (SLE) to identify subgroups at extraordinary risk for developing osteonecrosis.
METHODS: 31 of 103 (30%) patients with SLE had developed osteonecrosis. Patients were studied to identify clinical characteristics that differentiated patients with and without osteonecrosis. Subjects were studied to determine whether and to what degree factors leading to thrombophilia (anticardiolipin antibodies, aCL) or hypofibrinolysis [lipoprotein(a)] are associated with osteonecrosis.
RESULTS: Clinically, the patients with osteonecrosis had significant increases in Cushingoid body habitus, thrombophlebitis, vasculitis, cigarette smoking, and preeclampsia. Highest prednisone dose was positively associated with osteonecrosis. Although IgG aCL were also found to be associated with osteonecrosis, particularly in the white patients with SLE, lipoprotein(a) levels were not increased in either the white or black patients.
CONCLUSION: Maximal prednisone doses, changes in body habitus in response to corticosteroid therapy, IgG aCL levels, and clinical evidence of venous thrombosis and vasculitis were associated with osteonecrosis in patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9101497

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  41 in total

1.  Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies?

Authors:  M Y Mok; V T Farewell; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Clinical characteristics of avascular necrosis in patients with Behçet disease: a case series and literature review.

Authors:  Nuh Atas; Berivan Bitik; Ozkan Varan; Hakan Babaoglu; Abdurrahman Tufan; Seminur Haznedaroglu; Berna Goker; Mehmet Akif Ozturk
Journal:  Rheumatol Int       Date:  2018-12-17       Impact factor: 2.631

Review 3.  Steroid induced osteonecrosis: An analysis of steroid dosing risk.

Authors:  Christian Powell; Christopher Chang; Stanley M Naguwa; Gurtej Cheema; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2010-07-09       Impact factor: 9.754

Review 4.  Why targeted therapies are necessary for systemic lupus erythematosus.

Authors:  L Durcan; M Petri
Journal:  Lupus       Date:  2016-09       Impact factor: 2.911

5.  The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years?

Authors:  G Stojan; M Petri
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-07-27

Review 6.  Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy.

Authors:  Waqar Haque; Huseyin Kadikoy; Omar Pacha; Joseph Maliakkal; Vu Hoang; Abdul Abdellatif
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

7.  Uncommon case of tibial bone infarction associated with juvenile idiopathic arthritis.

Authors:  Yousra Ibn Yacoub; Samira Rostom; Bouchra Amine; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2010-04       Impact factor: 2.980

8.  A case of SLE with bilateral osteonecrosis of femoral heads and bone infarct in distal of femur.

Authors:  Mansour Salesi; Mansoor Karimifar; Peyman Mottaghi; Zahra Sayedbonakdar; Hadi Karimzadeh
Journal:  Rheumatol Int       Date:  2009-05-18       Impact factor: 2.631

9.  Heritable thrombophilia-hypofibrinolysis and osteonecrosis of the femoral head.

Authors:  Charles J Glueck; Richard A Freiberg; Ping Wang
Journal:  Clin Orthop Relat Res       Date:  2008-03-19       Impact factor: 4.176

10.  Management of avascular necrosis of femoral head at pre-collapse stage.

Authors:  Ramesh Kumar Sen
Journal:  Indian J Orthop       Date:  2009-01       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.